Dr. Luke on the Combination of Pembrolizumab and T-VEC for Melanoma

Jason Luke, MD
Published: Friday, Oct 27, 2017



Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the combination of pembrolizumab (Keytruda) and talimogene laherparepvec (T-VEC; Imlygic) for the treatment of patients with melanoma.

A combination that is of a lot of interest is a PD-1 antibody and an oncolytic virus, states Luke. There are drugs that are approved for each as a monotherapy, but the combination of pembrolizumab and T-VEC has the potential to be promising.

T-VEC is a modified virus that is injected into melanoma tumors that are on the skin.  


Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the combination of pembrolizumab (Keytruda) and talimogene laherparepvec (T-VEC; Imlygic) for the treatment of patients with melanoma.

A combination that is of a lot of interest is a PD-1 antibody and an oncolytic virus, states Luke. There are drugs that are approved for each as a monotherapy, but the combination of pembrolizumab and T-VEC has the potential to be promising.

T-VEC is a modified virus that is injected into melanoma tumors that are on the skin.  

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 28, 20182.0
Publication Bottom Border
Border Publication
x